Loss of CBX7 expression has been shown to correlate with a highly malignant phenotype and poor prognosis in patients with hepatocellular carcinoma (Zhu et al., 2019), glioma (Yu et al., 2017), pancreatic cancer (Karamitopoulou et al., 2010), breast cancer, thyroid cancer (Pallante et al., 2008), cervical cancer (Li et al., 2019), ovarian cancer (Shinjo et al., 2014), and colon cancer (Zheng et al., 2015), which supports the tumor-suppressive role of CBX7. Here, CBX7 is linked to ovarian carcinoma.